Insmed stock dropped after its brensocatib drug failed a key clinical trial. Despite the Insmed trial failure, analysts ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

Dr Philippa Kaye answers: A constantly runny or blocked nose would usually be due to a condition called rhinitis – ...

GSK plc (NYSE:GSK) is included among the 15 Global Dividend Stocks to Diversify Your Portfolio. On December 10, HSBC analyst ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

Treatments known as biologics - which work by switching off the immune system reaction that drives inflammation - are on the ...

Brits are being urged to check the colour of their snot as the new H3N2 subclade K flu spreads, with experts revealing said ...

Know when inhalers actually help blocked nose relief, when they can worsen congestion, and common mistakes doctors warn ...

I have carpal tunnel syndrome. I've been on the waiting list for surgery for two years, but what can I do now to ease the ...

For most of those features, of course, having two makes sense. A pair of eyes gives us a wider range of vision, depth ...

Insmed’s oral drug Brinsupri did not ease the burden of sinus symptoms in a mid-stage study of chronic rhinosinusitis without nasal polyps, forcing the New Jersey biotech to discontinue its program in ...

Shares of Insmed were lower after the pharmaceutical company said it was discontinuing development of its brensocatib treatment for patients with chronic rhinosinusitis without nasal polyps. Shares ...